The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Updates on CPX-351: real world experiences and studies in MDS
CPX-351 is a dual-drug liposomal formulation of cytarabine and daunorubicin, approved by the FDA for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) with myelodysplasia-related changes (AML-MRC) and therapy-related AML. Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses the latest news on CPX-351, including real-world experiences and trials in myelodysplastic syndrome (MDS). This interview took place at during 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
